| Demographic and treatment characteristics | Treatment group; no. (%) of patients* | p value | ||
|---|---|---|---|---|
| Overall n = 303 | Following docetaxel chemotherapy n = 99 | Without prior docetaxel chemotherapy (exception patients) n = 204 | ||
| Age at initiation of abiraterone therapy, yr | ||||
| Mean (95% CI) | 78.0 (77.1-78.9) | 74.5 (72.7-76.2) | 79.7 (78.8-80.7) | < 0.001 |
| Median (IQR) | 79.0 (73.0-84.0) | 75.0 (68.0-81.0) | 80.0 (76.0-84.0) | < 0.001 |
| Age at initiation of abiraterone therapy ≥ 70 yr | 254 (83.8) | 69 (69.7) | 185 (90.7) | < 0.001 |
| Age at initiation of abiraterone therapy ≥ 75 yr | 203 (67.0) | 48 (48.5) | 155 (76.0) | < 0.001 |
| Diagnosed metastasis | 264 (87.1) | 95 (96.0) | 169 (82.8) | 0.001 |
| Prior chemotherapy | 99 (32.7) | 99 (100) | 0 (0) | - |
| Received anti-androgens during CRPC | 43 (14.2) | 17 (17.2) | 26 (12.7) | 0.3 |
| Received LHRHa during CRPC | 238 (78.5) | 88 (88.9) | 150 (73.5) | 0.002 |
| Bone-targeted therapy | 226 (74.6) | 86 (86.9) | 140 (68.6) | < 0.001 |
| Palliative radiotherapy | 45 (14.9) | 25 (25.2) | 20 (9.8) | < 0.001 |
| Proximity to radiation oncology centre | 219 (72.3) | 69 (69.7) | 150 (73.5) | 0.5 |
| Rural residence | 61 (20.1) | 16 (16.2) | 45 (22.0) | 0.2 |
| Comorbidity | ||||
| Diabetes | 64 (21.1) | 15 (15.2) | 49 (24.0) | 0.1 |
| Dyslipidemia | 165 (54.4) | 53 (53.5) | 112 (54.9) | 0.8 |
| Hypertension | 225 (74.2) | 72 (72.7) | 153 (75.0) | 0.7 |
| Coronary heart disease | 78 (25.7) | 25 (25.2) | 53 (26.0) | 0.9 |
| Chronic heart failure | 27 (8.9) | 5 (5.1) | 22 (10.8) | 0.1 |
| Cerebrovascular disease | 10 (3.3) | 1 (1.0) | 9 (4.4) | 0.2† |
| Arrhythmia | 48 (15.8) | 8 (8.1) | 40 (19.6) | 0.01 |
| Von Korff Chronic Disease Score | ||||
| Mean (95% CI) | 12.0 (11.5-12.5) | 11.8 (11.0-12.6) | 12.0 (11.4-12.7) | 0.8 |
| Median (IQR) | 12.0 (9.0-15.0) | 12.0 (9.0-15.0) | 12.0 (9.0-15.0) | 0.9 |
Note: CI = confidence interval, IQR = interquartile range, LHRHa = luteinizing hormone-releasing hormone analogues, mCRPC = metastatic castration-resistant prostate cancer.
*Except where noted otherwise.
†Fisher exact test.